Compare Genuine Parts Company (GPC) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Eli Lilly And Co — how do they compare? Genuine Parts Company trades at $127.56 (market cap $17.67B), while Eli Lilly And Co trades at $1,164.15 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 58.9× Genuine Parts Company's market cap, and Genuine Parts Company pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Eli Lilly And Co for 93 Days on average.
| GPC | LLY | |
|---|---|---|
Market Cap | $17.67B | $1.04T |
Volume | 1,079,458 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $1.28K |
52-Week Low | $92.47 | $799.57 |
Typical Hold Time | 75 Days | 93 Days |
Enterprise Value | $23.76B | $1.09T |
Dividend Yield | 3.32% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.41, down 1.55% today, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 2026 results due October 20, 2026. Revenue grew to $24.3B in 2025, but net income margin fell sharply to 0.13%. Analyst consensus is a $145.75 price target with 43% buy ratings. Key developments include the planned spinoff of its industrial unit, Motion, in Q1 2027.
The outlook is cautious due to weak profitability and high P/E, but the spinoff could unlock value. Risks include execution challenges and economic sensitivity. Upside hinges on margin recovery and successful separation.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
